SNP-Based Rheumatoid Arthritis Risk Detection and Early Intervention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic criteria for rheumatoid arthritis (RA) are ineffective for early detection and cannot predict which patients will develop severe erosive disease, leading to irreversible joint damage, highlighting the need for novel diagnostic markers that can identify individuals predisposed to RA or detect the disease at an early stage.
Innovation Solution
Identification of specific single nucleotide polymorphisms (SNPs) associated with RA, which can be used to design diagnostic and prognostic reagents and therapeutic agents, predict patient responses to TNF inhibitors, and determine individual risk or predisposition to autoimmune disease, enabling early intervention and personalized treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current diagnostic criteria are used, then diagnosis can be made based on established criteria, but early detection is ineffective and cannot predict severe erosive disease
Solution Approach 1:
The patent applies preliminary action by identifying genetic markers (SNPs) before disease onset to predict susceptibility and early detection. The invention detects genetic polymorphisms that predispose individuals to RA, enabling intervention before clinical symptoms manifest or before severe joint damage occurs, thus resolving the contradiction between early detection accuracy and prediction reliability.
2Loss of time
If traditional diagnostic methods are used, then diagnosis is based on clinical criteria, but irreversible joint damage has already begun and cannot be prevented
Solution Approach 1:
The invention enables preliminary detection of RA susceptibility through genetic testing before clinical symptoms appear or before joint damage occurs. By identifying risk-associated SNPs in advance, the system allows timely intervention to prevent the harmful effect of irreversible joint damage, addressing both the time loss and harmful factor contradictions.
Solution Approach 2:
The patent converts the previously harmful factor of genetic susceptibility (which caused premature joint damage) into a beneficial predictive marker. By detecting SNP patterns that indicate high risk, the system transforms what was once a silent precursor to damage into an actionable diagnostic tool that enables preventive treatment, thereby preventing the harmful effect.
3Measurement precision
If genetic markers are identified, then early detection and prediction are improved, but diagnostic and prognostic reagents must be designed and developed
Solution Approach 1:
The patent applies segmentation by focusing on specific, discrete SNP markers rather than attempting to analyze the entire genome. The invention identifies and tests specific polymorphic sites (such as those in the HLA-DRB1 gene) that are associated with RA susceptibility, breaking down the complex task of genetic analysis into manageable, targeted segments that can be detected with relatively simple reagents.
Solution Approach 2:
The invention extracts and isolates specific genetic markers (SNPs) from the complex genetic background. By taking out only the relevant polymorphic sites that are statistically associated with RA risk, the system simplifies the detection process and reduces the complexity of required reagents while maintaining high prediction accuracy.
4Reliability
If personalized treatment approaches are implemented, then patient outcomes are improved, but treatment strategies must be customized for each individual
Solution Approach 1:
The patent applies local quality by tailoring treatment strategies to specific genetic profiles. Instead of using a one-size-fits-all approach, the system identifies which SNP markers an individual carries and customizes treatment recommendations accordingly. For example, patients with specific HLA-DRB1 SNP patterns may be prescribed different therapies or dosing regimens, creating localized treatment quality matched to individual genetic characteristics.
Data Source
AI summary
The present invention provides compositions and methods based on genetic polymorphisms that are associated with autoimmune disease, particularly rheumatoid arthritis. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.